| D06623 | |
| D number | D06623 |
| Classification | Drug |
| Name | Olanzapine pamoate (USAN); Olanzapine pamoate monohydrate |
| Component | - |
| Formula | C23H16O6. C17H20N4S. H2O |
| Exact mass | 718.2461 |
| Mol weight | 718.8173 |
| Structural formula |  |
| Sequence | - |
| Sequence type | - |
| Source | - |
| Upper DGroup | Cardiovascular agent DG01466 Adrenergic receptor antagonist DG01465 alpha-Adrenergic receptor antagonist DG01457 alpha1-Adrenergic receptor antagonist Neuropsychiatric agent DG01478 Dopamine antagonist DG01474 Dopamine D2-receptor antagonist DG01475 Dopamine D3-receptor antagonist DG01476 Dopamine D4-receptor antagonist Anti-allergic agent DG01557 Histamine receptor antagonist DG01482 Histamine receptor H1 antagonist Cyp substrate DG01892 CYP1A2 substrate DG01644 CYP2D6 substrate |
| Remark | ATC code: N05AH03 Chemical group: DG00898 |
| Activity | - |
| Disease | - |
| Comment | Multi-acting-receptor-targeting-antipsychotics (MARTA) Treatment of schizophrenia |
| Target | HTR2 [HSA:3356 3357 3358] [KO:K04157]; HTR6 [HSA:3362] [KO:K04162]; HRH1 [HSA:3269] [KO:K04149]; ADRA1 [HSA:148 147 146] [KO:K04135 K04136 K04137]; DRD2 [HSA:1813] [KO:K04145]; DRD3 [HSA:1814] [KO:K04146]; DRD4 [HSA:1815] [KO:K04147] |
| Metabolism | Enzyme: CYP1A2 [HSA:1544]; CYP2D6 [HSA:1565] |
| Interaction | |
| Other DBs | CAS: 221373-18-8 PubChem: 47208274 DrugBank: DB00334 LigandBox: D06623 |
| KCF data | - |